Takeda announces that the US Food and Drug Administration has approved FRUZAQLA™ (fruquintinib), an oral therapy for adult patients with previously treated metastatic colorectal cancer (mCRC).1,*

*FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with mCRC who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy.1

CRC is the 4th most common cancer in the US, and up to 50% of patients with CRC will progress to mCRC. The 5-year relative survival rate of mCRC is only ~15%.2,3

Store at 20 °C to 25 °C (68 °F to 77 °F). Brief exposure to 15 °C and 30 °C (59 °F to 86 °F) permitted (see USP Controlled Room Temperature).1 Any unused medicinal product or waste material should be disposed of in accordance with local requirements.1 DISTRIBUTION FRUZAQLA is available by prescription through Biologics and Onco360 Specialty Pharmacies. Practices may also arrange for in-office dispensing via ASD Healthcare and Cardinal Health. Takeda Oncology Here2Assist® Takeda Oncology Here2Assist is a comprehensive support program committed to helping your patients navigate coverage requirements, identify available financial assistance, and connect with helpful resources throughout their treatment. For more information about patient access support and financial assistance that your patients may qualify for, call us at 1-844-817-6468, Option 2. Let’s Talk. We’re available Monday–Friday, 8AM–8PM ET, or visit us at www.Here2Assist.com/hcp to learn more.  
Pease click here to review more information on FRUZAQLA.

No comments have been posted yet.